| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study was to investigate the mechanism of how HMG-CoA reductase inhibitors (statins) play a role of antithrombotic properties. In our in-vitro experiments, fluvastatin increased tissue factor pathway inhibitor (TFPI) expression in human umbilical vein endothelial cells. Fluvastatin also increased a disintegrin and metalloproteinase with a thrombosponsin type 1 motif, menber 13 (ADAMTS13) expression in human hepatic stellate cells. Both TFPI and ADAMTS13 play crucial roles in inhibition of thrombus formation. This study revealed unknown mechanisms of the anticoagulant effect of statins and gave a new insight to its therapeutic potential for the prevention of thrombotic diseases.
|
